CTCM Round 1 Expressions of Interest have now closed
The Clinical Translation and Commercialisation - Medtech (CTCM) program, delivered by MTPConnect, is offered under the 2020 Early Stage Translation and Commercialisation Support Grant of the Medical Research Future Fund's Medical Research Commercialisation Initiative.
The $19.75 million CTCM program is targeting Australian small to medium-sized enterprises (SMEs) and aims to boost commercialisation of home-grown medical devices.
The CTCM program can provide between $250,000 and $1.5 million to SMEs to support early clinical development of medical devices with commercial potential.
Projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body. Funding will only be awarded to projects where the device’s capability has already been validated with research and/or preclinical studies.
SMEs are defined as having 199 employees or less. To be eligible, applicants are required to provide a co-contribution to the value of 50 percent of the CTCM funding request. Additional in-kind or cash contributions above this threshold will be viewed favourably.
Please review the detailed Funding Guidelines for further information about eligibility and the application process. The sample EOI application form provides an overview of what is required in the EOI. All submissions must be made online through SmartyGrants via the 'Apply here' link below.
Applications for CTCM Round 1 funding are now closed. Round 1 is under assessment. Watch this space for awardee announcements.